Kyverna Therapeutics, Inc. Common Stock
Rachunek Zysków i Strat
index |
0 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
Rok finansowy |
2022 |
2023 |
2023 |
2023 |
2023 |
2024 |
2024 |
2024 |
2024 |
2025 |
Kwartał |
Q4 |
Q1 |
Q2 |
Q3 |
Q4 |
Q1 |
Q2 |
Q3 |
Q4 |
Q1 |
Data |
2022-12-31 |
2023-03-31 |
2023-06-30 |
2023-09-30 |
2023-12-31 |
2024-03-31 |
2024-06-30 |
2024-09-30 |
2024-12-31 |
2025-03-31 |
Przychód (mln) |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Przychód Δ kw/kw |
0.0% |
0.0% |
0.0% |
0.0% |
-100.00% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
Marża brutto |
-32.62% |
-inf% |
-inf% |
-inf% |
-inf% |
-inf% |
-inf% |
0.0% |
0.0% |
0.0% |
Koszty i Wydatki (mln) |
9 |
11 |
13 |
16 |
21 |
29 |
33 |
39 |
41 |
0 |
EBIT (mln) |
-9 |
-11 |
-13 |
-16 |
-21 |
-29 |
-33 |
-39 |
-41 |
-47 |
EBIT Δ kw/kw |
0.0% |
0.0% |
0.0% |
0.0% |
143.6% |
156.5% |
151.4% |
138.1% |
92.0% |
61.5% |
EBIT (%) |
-3111.70% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
nan |
nan |
Przychody fiansowe (mln) |
0 |
0 |
0 |
1 |
1 |
3 |
5 |
4 |
4 |
3 |
Koszty finansowe (mln) |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
-0 |
Amortyzacja (mln) |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
0 |
EBITDA (mln) |
-8 |
-11 |
-13 |
-15 |
-20 |
-26 |
-28 |
-34 |
-37 |
-47 |
EBITDA(%) |
-2865.60% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
nan |
nan |
NOPLAT (mln) |
-8 |
-11 |
-13 |
-15 |
-21 |
-27 |
-29 |
-34 |
-37 |
-45 |
Podatek (mln) |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Zysk Netto (mln) |
-8 |
-11 |
-13 |
-15 |
-21 |
-27 |
-29 |
-34 |
-37 |
-45 |
Zysk netto Δ kw/kw |
0.0% |
0.0% |
0.0% |
0.0% |
143.3% |
139.5% |
120.0% |
123.0% |
81.4% |
67.2% |
Zysk netto (%) |
-3012.77% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
0.0% |
nan |
nan |
EPS |
-0.2 |
-0.43 |
-0.3 |
-0.36 |
-0.48 |
-1.12 |
-0.67 |
-0.8 |
-0.92 |
-1.03 |
EPS (rozwodnione) |
-0.2 |
-0.43 |
-0.3 |
-0.36 |
-0.48 |
-1.12 |
-0.67 |
-0.8 |
-0.92 |
-1.03 |
Ilośc akcji (mln) |
43 |
26 |
43 |
43 |
43 |
24 |
43 |
43 |
41 |
43 |
Ważona ilośc akcji (mln) |
43 |
26 |
43 |
43 |
43 |
24 |
43 |
43 |
41 |
43 |
Waluta |
USD |
USD |
USD |
USD |
USD |
USD |
USD |
USD |
USD |
USD |